Neurocrine Biosciences Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||
| 27.8 | 28.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | 12.7 | 99.9 | – | – | – | – | – | 322.7 | 278.1 | 23.0 | 93.1 | 76.4 | 53.3 | 41.5 | 30.4 | |
| 8.5 | 5.5 | 7.8 | 28.2 | 50.2 | 32.4 | 77.2 | 12.7 | 21.0 | 19.2 | 10.0 | 139.7 | 31.0 | 35.8 | 12.0 | 6.2 | 9.4 | 213.4 | – | 241.9 | 223.7 | 42.3 | 15.1 | 13.1 | 9.0 | 7.4 | 7.9 | 7.1 | 6.0 | 5.1 | |
| 2.3 | 1.7 | 1.7 | 4.9 | 4.5 | 4.3 | 6.2 | 4.5 | 4.5 | 6.1 | 1.2 | 1.4 | 3.3 | 26.7 | 20.8 | 8.0 | 3.3 | 5.2 | 8.0 | 11.3 | 10.7 | 18.4 | 14.2 | 16.2 | 8.3 | 6.1 | 6.9 | 6.0 | 5.5 | 4.5 | |
| 8.0 | 4.9 | 7.1 | 26.9 | 49.0 | 28.5 | 75.2 | 12.2 | 21.0 | 19.3 | 9.3 | 148.4 | 15.7 | 24.6 | 10.6 | 5.6 | 8.5 | 198.1 | – | 238.8 | 219.2 | 43.2 | 15.8 | 14.0 | 9.1 | 7.4 | 7.9 | 7.0 | – | – | |
| 306.8 | 71.7 | – | – | – | – | – | – | – | – | – | – | – | – | – | 12.6 | 213.6 | – | – | – | – | – | 174.0 | 128.0 | 64.3 | 60.5 | 44.3 | 31.8 | – | – | |
| 32.1 | 31.3 | – | – | – | – | – | – | – | – | – | – | – | – | 8.1 | – | – | – | – | – | – | – | 88.9 | 77.8 | 43.1 | 35.8 | 36.6 | 36.8 | 25.4 | 19.4 | |
| 3.1% | 3.2% | -11.5% | -2.6% | -2.9% | -1.9% | -6.1% | -0.8% | -8.6% | -1.6% | -26.1% | -35.1% | -61.4% | -50.3% | 12.4% | -0.3% | -7.2% | -4.8% | -2.9% | -0.8% | -3.3% | -1.5% | 1.1% | 1.3% | 2.3% | 2.8% | 2.7% | 2.7% | 3.9% | 5.2% | |
| Margins | ||||||||||||||||||||||||||||||
| 105.2% | 105.0% | 110.6% | 112.5% | 115.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 78.2% | -372.8% | – | 100.0% | 100.0% | 99.2% | 98.9% | 99.1% | 99.0% | 98.7% | 98.4% | 97.9% | 98.6% | 98.2% | |
| 15.1% | 1.9% | -77.5% | -118.5% | -244.0% | -106.4% | -574.2% | -42.3% | -61.4% | -20.2% | -288.8% | -17,340.0% | -2,196.2% | -1,817.5% | -41.0% | 43.8% | 2.7% | -1,701.9% | – | -476.5% | -982.5% | -81.3% | 8.2% | 9.2% | 15.6% | 9.0% | 16.7% | 13.3% | 24.2% | 21.6% | |
| 30.7% | 19.5% | -125.0% | -100.0% | -197.5% | -89.5% | -523.9% | -21.8% | -53.7% | -17.9% | -273.2% | -16,936.2% | -2,229.3% | -1,728.3% | -23.8% | 48.5% | 9.5% | -1,579.0% | – | -449.8% | -940.6% | -88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% | |
| 26.6% | 17.6% | -90.0% | -73.8% | -144.5% | -62.2% | -469.2% | -9.6% | -179.8% | -30.7% | -261.1% | -4,898.5% | -1,899.0% | -1,799.2% | 148.1% | -1.9% | -68.2% | -1,033.0% | – | -202.0% | -735.3% | -62.7% | 17.0% | 16.8% | 20.8% | 20.6% | 21.7% | 19.2% | 23.7% | 26.2% | |
| Returns | ||||||||||||||||||||||||||||||
| 8.1% | 6.1% | -27.8% | -17.4% | -17.7% | -11.9% | -42.2% | -7.7% | -11.6% | -5.7% | -34.1% | -174.6% | -241.0% | -1,290.8% | -41.2% | 62.5% | 3.3% | -38.3% | -29.0% | -21.0% | -44.8% | -38.3% | 4.4% | 5.8% | 36.2% | 6.5% | 9.0% | 11.2% | 13.2% | 14.7% | |
| 7.6% | 5.5% | -24.8% | -15.4% | -15.5% | -10.7% | -35.5% | -5.5% | -8.8% | -4.6% | -27.5% | -74.9% | -75.0% | -72.1% | -5.5% | 27.2% | 2.6% | -29.8% | -24.9% | -18.7% | -38.6% | -17.4% | 2.1% | 2.8% | 23.5% | 4.3% | 6.5% | 7.7% | 9.2% | 10.3% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||
| -11 | -15 | -11 | -20 | -17 | -158 | -36 | -69 | 5.1 | 9.5 | -27 | 11 | -61 | -33 | -45 | -42 | -53 | -45 | -31 | -62 | -68 | 153 | 309 | 705 | 141 | 11 | -94 | -81 | – | – | |
| -21.0 | -8.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | -1.2 | -25.0 | – | – | – | – | – | 7.6 | 8.2 | 1.0 | 0.1 | -0.4 | -0.2 | – | – | |
| 93.3% | 90.5% | 89.4% | 88.3% | 87.8% | 89.6% | 84.1% | 70.5% | 75.9% | 80.7% | 80.8% | 42.9% | 31.1% | 5.6% | 13.4% | 43.4% | 78.8% | 77.8% | 85.9% | 89.4% | 86.2% | 45.5% | 48.4% | 48.8% | 64.9% | 66.3% | 72.1% | 68.6% | 69.6% | 70.2% | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.2 | 0.2 | 0.9 | 0.2 | 1.1 | 0.4 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 0.9 | 1.3 | 0.3 | 0.3 | 0.1 | 0.1 | – | – | |
| Per Share | ||||||||||||||||||||||||||||||
| 0.36 | 0.28 | -1.10 | -0.88 | -1.30 | -1.42 | -3.10 | -0.93 | -1.26 | -0.58 | -2.84 | -5.45 | -2.30 | -1.30 | -0.15 | 0.67 | 0.08 | -0.69 | -0.81 | -1.05 | -1.63 | -1.62 | 0.22 | 0.39 | 4.16 | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 | |
| 1.17 | 1.43 | 0.88 | 0.88 | 0.66 | 1.58 | 0.59 | 4.30 | 2.35 | 3.26 | 1.04 | 0.03 | 0.10 | 0.08 | 0.63 | 1.37 | 0.79 | 0.04 | 0.00 | 0.23 | 0.17 | 1.83 | 4.73 | 8.23 | 10.69 | 11.58 | 15.05 | 18.68 | 22.71 | 27.91 | |
| 4.44 | 4.57 | 3.97 | 5.05 | 7.38 | 11.93 | 7.36 | 12.08 | 10.88 | 10.27 | 8.34 | 3.12 | 0.96 | 0.10 | 0.37 | 1.07 | 2.31 | 1.80 | 2.80 | 5.02 | 3.63 | 4.22 | 5.04 | 6.65 | 11.52 | 14.03 | 17.27 | 22.10 | 24.97 | 31.74 | |
| 0.31 | 0.25 | -0.79 | -0.65 | -0.95 | -0.99 | -2.78 | -0.41 | -4.23 | -1.00 | -2.72 | -1.58 | -1.96 | -1.36 | 0.94 | -0.03 | -0.54 | -0.45 | -0.65 | -0.47 | -1.27 | -1.15 | 0.80 | 1.38 | 2.22 | 2.38 | 3.26 | 3.58 | 5.37 | 7.30 | |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.